160 related articles for article (PubMed ID: 36441756)
21. Sporadic and Von-Hippel Lindau disease-associated spinal hemangioblastomas: institutional experience on their similarities and differences.
Yousef A; Rutkowski MJ; Yalcin CE; Eren OC; Caliskan I; Tihan T
J Neurooncol; 2019 Jul; 143(3):547-552. PubMed ID: 31089924
[TBL] [Abstract][Full Text] [Related]
22. [Von Hippel-Lindau disease and central nervous system hemangioblastoma. Progress in genetics and clinical management].
Richard S; Martin S; David P; Decq P
Neurochirurgie; 1998 Nov; 44(4):258-66. PubMed ID: 9864697
[TBL] [Abstract][Full Text] [Related]
23. Molecular pathology of eyes with von Hippel-Lindau (VHL) Disease: a review.
Chan CC; Collins AB; Chew EY
Retina; 2007 Jan; 27(1):1-7. PubMed ID: 17218907
[TBL] [Abstract][Full Text] [Related]
24. Management of von Hippel-Lindau disease-associated CNS lesions.
Wind JJ; Lonser RR
Expert Rev Neurother; 2011 Oct; 11(10):1433-41. PubMed ID: 21955200
[TBL] [Abstract][Full Text] [Related]
25. Central nervous system hemangioblastomas, endolymphatic sac tumors, and von Hippel-Lindau disease.
Richard S; David P; Marsot-Dupuch K; Giraud S; Béroud C; Resche F
Neurosurg Rev; 2000 Mar; 23(1):1-22; discussion 23-4. PubMed ID: 10809480
[TBL] [Abstract][Full Text] [Related]
26. Notch receptor and effector expression in von Hippel-Lindau disease-associated central nervous system hemangioblastomas.
Merrill MJ; Edwards NA; Lonser RR
J Neurosurg; 2011 Sep; 115(3):512-7. PubMed ID: 21663414
[TBL] [Abstract][Full Text] [Related]
27. Variable response of CNS hemangioblastomas to Pazopanib in a single patient with von Hippel-Lindau disease: Case report.
Taylor DG; Ilyas A; Mehta GU; Chen CJ; Schiff D; Oldfield EH; Asthagiri AR
J Clin Neurosci; 2018 Apr; 50():154-156. PubMed ID: 29396065
[TBL] [Abstract][Full Text] [Related]
28. Hemangioblastomas of central nervous system: molecular genetic analysis and clinical management.
Catapano D; Muscarella LA; Guarnieri V; Zelante L; D'Angelo VA; D'Agruma L
Neurosurgery; 2005 Jun; 56(6):1215-21; discussion 1221. PubMed ID: 15918937
[TBL] [Abstract][Full Text] [Related]
29. [Von Hippel-Lindau disease: recent genetic progress and patient management. Francophone Study Group of von Hippel-Lindau Disease (GEFVH)].
Richard S; Giraud S; Beroud C; Caron J; Penfornis F; Baudin E; Niccoli-Sire P; Murat A; Schlumberger M; Plouin PF; Conte-Devolx B
Ann Endocrinol (Paris); 1998; 59(6):452-8. PubMed ID: 10189987
[TBL] [Abstract][Full Text] [Related]
30. [Intravitreal anti-VEGF therapy for capillary hemangioblastomas in von Hippel-Lindau disease].
Michels S; Messmer E; Sutter F; Kurz-Levin MM
Klin Monbl Augenheilkd; 2008 Apr; 225(4):292-4. PubMed ID: 18401796
[TBL] [Abstract][Full Text] [Related]
31. Hemangioblastoma and von Hippel-Lindau disease: genetic background, spectrum of disease, and neurosurgical treatment.
Klingler JH; Gläsker S; Bausch B; Urbach H; Krauss T; Jilg CA; Steiert C; Puzik A; Neumann-Haefelin E; Kotsis F; Agostini H; Neumann HPH; Beck J
Childs Nerv Syst; 2020 Oct; 36(10):2537-2552. PubMed ID: 32507909
[TBL] [Abstract][Full Text] [Related]
32. A 10-year retrospective study of hemangioblastomas of the central nervous system with reference to von Hippel-Lindau (VHL) disease.
Padhi S; Sarangi R; Challa S; Bussary P; Panigrahi MK; Purohit AK
J Clin Neurosci; 2011 Jul; 18(7):939-44. PubMed ID: 21570297
[TBL] [Abstract][Full Text] [Related]
33. The β2-adrenergic receptor antagonist ICI-118,551 blocks the constitutively activated HIF signalling in hemangioblastomas from von Hippel-Lindau disease.
Cuesta AM; Albiñana V; Gallardo-Vara E; Recio-Poveda L; de Rojas-P I; de Las Heras KVG; Aguirre DT; Botella LM
Sci Rep; 2019 Jul; 9(1):10062. PubMed ID: 31296894
[TBL] [Abstract][Full Text] [Related]
34. Biological and clinical impact of hemangioblastoma-associated peritumoral cysts in von Hippel-Lindau disease.
Huntoon K; Wu T; Elder JB; Butman JA; Chew EY; Linehan WM; Oldfield EH; Lonser RR
J Neurosurg; 2016 Apr; 124(4):971-6. PubMed ID: 26517769
[TBL] [Abstract][Full Text] [Related]
35. Psychological impact of von Hippel-Lindau genetic screening in patients with a previous history of hemangioblastoma of the central nervous system.
Rochette C; Baumstarck K; Canoni-Zattara H; Abdullah AE; Figarella-Branger D; Pertuit M; Barlier A; Castinetti F; Pacak K; Metellus P; Taïeb D
J Psychosoc Oncol; 2018; 36(5):624-634. PubMed ID: 29764331
[TBL] [Abstract][Full Text] [Related]
36. Developmental effects of von Hippel-Lindau gene deficiency.
Vortmeyer AO; Yuan Q; Lee YS; Zhuang Z; Oldfield EH
Ann Neurol; 2004 May; 55(5):721-8. PubMed ID: 15122713
[TBL] [Abstract][Full Text] [Related]
37. [Epidemiology, treatment and follow-up of central nervous system hemangioblastomas in von Hippel-Lindau disease].
Sankaredja J; Brac B; Thines L; Baroncini M; Zairi F; Cardot-Bauters C; Lejeune JP
Rev Neurol (Paris); 2014 Apr; 170(4):288-96. PubMed ID: 24680832
[TBL] [Abstract][Full Text] [Related]
38. Expression of vascular endothelial growth factor in von Hippel-Lindau syndrome-associated papillary cystadenoma of the epididymis.
Leung SY; Chan AS; Wong MP; Yuen ST; Fan YW; Chung LP
Hum Pathol; 1998 Nov; 29(11):1322-4. PubMed ID: 9824115
[TBL] [Abstract][Full Text] [Related]
39. Haemangioblastoma of the central nervous system in von Hippel-Lindau disease. French VHL Study Group.
Richard S; Campello C; Taillandier L; Parker F; Resche F
J Intern Med; 1998 Jun; 243(6):547-53. PubMed ID: 9681857
[TBL] [Abstract][Full Text] [Related]
40. von Hippel-Lindau disease-associated hemangioblastomas are derived from embryologic multipotent cells.
Park DM; Zhuang Z; Chen L; Szerlip N; Maric I; Li J; Sohn T; Kim SH; Lubensky IA; Vortmeyer AO; Rodgers GP; Oldfield EH; Lonser RR
PLoS Med; 2007 Feb; 4(2):e60. PubMed ID: 17298169
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
